Literature DB >> 32038762

New and Emerging Topical Therapies for Psoriasis and Atopic Dermatitis.

Corinna E Psomadakis1, George Han1.   

Abstract

Psoriasis and atopic dermatitis represent two of the most common skin conditions seen by both primary care and specialist dermatology. The prevalence of psoriasis in North America is 2 to 4 percent, and it is estimated to cost more than $3 billion per year to treat this condition. Atopic dermatitis has an estimated 15 to 30 percent lifetime prevalence in children and an 8 to 10 percent lifetime prevalence in adults. Both diseases have a significant impact on patient quality of life, as well as associated psychological, social, and economic consequences. While systemic therapies are available for both, the majority of patients with each condition are treated with topical therapies alone, with varying degrees of efficacy and patient satisfaction. As such, there is both need and an incentive to develop new treatments for these two conditions. In this paper, we review new and emerging topical therapies for psoriasis and atopic dermatitis.
Copyright © 2019. Matrix Medical Communications. All rights reserved.

Entities:  

Keywords:  Benvitimod; Crisaborole; Eucrisa; GATA-3; Genador; JAK inhibitor; JAKSTAT; PDE4 inhibitor; PH-10; Pefcalcitol; Psoriasis; Tofacitinib; atopic dermatitis; eczema; enstilar; hydroxypropyl-chitosan; phosphodiesterase-4 inhibitor; retinoids; sernivo; steroid; tazarotene; topical; vitamin D analog

Year:  2019        PMID: 32038762      PMCID: PMC7002051     

Source DB:  PubMed          Journal:  J Clin Aesthet Dermatol        ISSN: 1941-2789


  8 in total

1.  DRM02, a novel phosphodiesterase-4 inhibitor with cutaneous anti-inflammatory activity.

Authors:  David W C Hunt; Iordanka A Ivanova; Lina Dagnino
Journal:  Tissue Barriers       Date:  2020-06-01

Review 2.  Pruritus in psoriasis and atopic dermatitis: current treatments and new perspectives.

Authors:  Shirin Kahremany; Lukas Hofmann; Marco Harari; Arie Gruzman; Guy Cohen
Journal:  Pharmacol Rep       Date:  2021-01-18       Impact factor: 3.024

3.  Effect of herbal cream containing Fumaria officinalis and silymarin for treatment of eczema: A randomized double-blind controlled clinical trial.

Authors:  Fariba Iraji; Behzad Sharif Makhmalzadeh; Mahya Abedini; Ali Aghaei; Amir Siahpoush
Journal:  Avicenna J Phytomed       Date:  2022 Mar-Apr

4.  Coupling AFM, DSC and FT-IR towards Elucidation of Film-Forming Systems Transformation to Dermal Films: A Betamethasone Dipropionate Case Study.

Authors:  Mirjana D Timotijević; Tanja Ilić; Bojan Marković; Danijela Randjelović; Nebojša Cekić; Ines Nikolić; Snežana Savić; Ivana Pantelić
Journal:  Int J Mol Sci       Date:  2022-05-27       Impact factor: 6.208

5.  Effect of acupuncture treatment in patients with mild to moderate atopic dermatitis: a randomized, participant- and assessor-blind sham-controlled trial.

Authors:  Jung Gun Park; Hyangsook Lee; Mijeong Yeom; Younbyoung Chae; Hi-Joon Park; Kyuseok Kim
Journal:  BMC Complement Med Ther       Date:  2021-04-29

6.  Monovalent antibody-conjugated lipid-polymer nanohybrids for active targeting to desmoglein 3 of keratinocytes to attenuate psoriasiform inflammation.

Authors:  Zih-Chan Lin; Tsong-Long Hwang; Tse-Hung Huang; Kohei Tahara; Jiří Trousil; Jia-You Fang
Journal:  Theranostics       Date:  2021-03-04       Impact factor: 11.556

Review 7.  Tackling the various classes of nano-therapeutics employed in topical therapy of psoriasis.

Authors:  Salma A Fereig; Ghada M El-Zaafarany; Mona G Arafa; Mona M A Abdel-Mottaleb
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

Review 8.  Psoriasis: From Pathogenesis to Pharmacological and Nano-Technological-Based Therapeutics.

Authors:  Robert Gironés Petit; Amanda Cano; Alba Ortiz; Marta Espina; Josefina Prat; Montserrat Muñoz; Patrícia Severino; Eliana B Souto; Maria L García; Montserrat Pujol; Elena Sánchez-López
Journal:  Int J Mol Sci       Date:  2021-05-07       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.